Does Medicare Part D cover Wegovy for weight loss in 2026?

Medicare Part D does not routinely cover Wegovy for chronic weight management as of 2026. The Medicare Modernization Act historically excluded obesity drugs from Part D coverage. However, Part D plans may cover GLP-1 medications when prescribed for type 2 diabetes (Ozempic, Mounjaro) under standard formulary rules. Wegovy-specific obesity coverage requires checking your plan's formulary or pursuing a formulary exception with medical necessity documentation.

Did the 2023 Medicare law change GLP-1 weight loss drug coverage?

Congress expanded Medicare negotiation authority under the Inflation Reduction Act, but it did not automatically add obesity drug coverage to Part D. Some policy proposals have discussed expanding Medicare coverage for weight-loss medications, but enrollment in Part D still depends on each plan's drug list. Always verify your specific Part D Summary of Benefits rather than relying on general news headlines.

Can Medicare Advantage plans cover Wegovy when Part D does not?

Medicare Advantage (Part C) plans must cover everything Original Medicare covers, but Part D drug benefits are administered through embedded or standalone Part D plans. A Medicare Advantage plan cannot add obesity drug coverage beyond what its Part D component allows unless the drug is covered under a medical benefit for a covered diagnosis. Check both your MA plan documents and the associated Part D formulary.

What is the success rate for Medicare Part D GLP-1 appeals?

Formulary exception requests for GLP-1 medications succeed roughly 25–40% on first submission when supported by complete clinical documentation — lower than commercial ERISA plans because Part D obesity exclusions are explicit. Appeals citing diabetes indications with supporting HbA1c and diagnosis codes (E11.x) have higher overturn rates than pure obesity (E66.x) requests on plans that exclude weight-management GLP-1s.

Does Medicare cover Ozempic but not Wegovy for the same patient?

Yes. Ozempic (semaglutide 0.5–2 mg) is FDA-approved for type 2 diabetes and appears on most Part D formularies with prior authorization. Wegovy (semaglutide 2.4 mg) is FDA-approved for obesity and is often excluded. If you have type 2 diabetes with obesity, your prescriber may document medical necessity for a covered GLP-1 at an obesity-effective dose — but plans may still enforce step therapy or quantity limits.

What if my Medicare Part D appeal is denied — can I request an independent review?

Yes. After a Part D plan denies a formulary exception or coverage determination, you can request a redetermination, then a reconsideration by an Independent Review Entity (IRE). You have 60 days from the plan's denial to file each level. The IRE is not employed by your plan and evaluates medical necessity independently.

Can AppealFlow help with a Medicare GLP-1 coverage appeal letter?

Yes. AppealFlow.net offers a free GLP-1 appeal letter generator that drafts formulary exception and Part D appeal language citing FDA indication criteria, failed therapies, and appeal rights. Customize the letter for your Medicare plan, attach clinical documentation, and export to PDF or Word — no account required.

Does Medicare Cover Weight Loss Drugs Like Wegovy in 2026?

Q: How do I request a Medicare Part D formulary exception for Wegovy?

Submit a formulary exception request to your Part D plan with a prescriber statement explaining why Wegovy is medically necessary and why covered alternatives are ineffective or intolerable. Include BMI documentation, comorbidity records, and evidence of failed prior therapies. Part D plans must respond within 72 hours for expedited requests or 24 hours when the prescriber certifies that delay poses serious health risk.

By Medical Claims Advocacy Team•13 min read•Updated August 2026

Medicare Part D generally does not cover Wegovy for obesity in 2026 because federal law historically excludes weight-loss drugs from the Part D benefit. Most plans cover GLP-1 medications for type 2 diabetes (Ozempic, Mounjaro) with prior authorization. Beneficiaries seeking Wegovy must request a formulary exception with medical necessity documentation or pursue an independent review after denial.

Medicare Part D Rules for Weight Loss Medications in 2026

Key Takeaway: Part D covers drugs for medically accepted indications — obesity drugs were excluded from Medicare coverage for decades. Wegovy's FDA approval for chronic weight management does not automatically add it to Part D formularies. Check your plan's drug list before assuming coverage.

When patients ask whether Medicare covers Wegovy, the answer depends on which Medicare benefit applies and what diagnosis the prescriber documents. Original Medicare (Part A/B) does not include outpatient prescription drug coverage — that comes through Part D or Medicare Advantage with drug coverage.

The statutory framework matters: Medicare Part D plans cannot cover drugs used for anorexia, weight gain, or weight loss under longstanding federal policy. Wegovy falls into this exclusion even though it treats obesity as a chronic disease. This is different from commercial employer plans, where obesity coverage varies by employer design.

Part D standalone plans: Check formulary on Medicare.gov/plan-compare or your plan's member portal
Medicare Advantage with Part D (MA-PD): Drug coverage follows the embedded Part D formulary — same obesity exclusion typically applies
Part B medical benefit: Rarely covers GLP-1 injections except in specific clinical scenarios billed as physician-administered drugs

Wegovy vs. Ozempic: Why Medicare May Cover One but Not the Other

Key Takeaway: Same molecule (semaglutide) at different doses and FDA indications produces different Part D coverage outcomes. Diabetes indication (Ozempic, E11.x) routes through standard prior auth; obesity indication (Wegovy, E66.x) hits the weight-loss exclusion on most plans.

This is the most common confusion I see among Medicare beneficiaries. Ozempic and Wegovy are both semaglutide manufactured by Novo Nordisk, but they carry different FDA-approved uses and dosing schedules.

Drug	FDA Indication	Typical Part D Status
Ozempic	Type 2 diabetes (E11.x)	Often on formulary with prior auth and step therapy
Wegovy	Chronic weight management (E66.x)	Usually excluded — obesity drug exclusion applies
Mounjaro	Type 2 diabetes (E11.x)	Often on formulary with prior auth

Prescribing Ozempic for a patient whose primary need is weight loss without documented type 2 diabetes creates audit risk for the prescriber and may result in claim denial or coverage investigation. Document clinical rationale honestly — appeals built on mismatched diagnoses fail more often than they succeed.

How to Request a Medicare Part D Formulary Exception for Wegovy

Key Takeaway: A formulary exception is your primary pathway when Wegovy is not on your Part D drug list. Submit a prescriber statement, clinical records, and evidence that covered alternatives are ineffective or intolerable. Expedited review is available when delay poses serious health risk.

Confirm Wegovy is excluded. Search your plan formulary on Medicare.gov or your Part D plan portal. Note whether it is “not covered” vs. “requires prior authorization.”
Get a prescriber statement of medical necessity. Must explain why Wegovy is required and why formulary alternatives fail. Include BMI, comorbidities, and failed prior therapies with dates.
Submit the exception request. Call your Part D plan or use the plan's online portal. Request expedited review if your physician certifies urgency.
Track the decision deadline. Expedited: 24–72 hours. Standard: 72 hours for exception requests. Document every call with representative name and reference number.
If denied, file a Part D appeal. Redetermination → reconsideration → Independent Review Entity (IRE). Each level has a 60-day filing window from the prior denial.

Weak vs. Strong Medicare GLP-1 Appeal Language (Before & After)

Key Takeaway: Part D reviewers approve exceptions when clinical documentation matches plan criteria — not when patients express frustration. Replace emotional appeals with dated metrics, ICD-10 codes, and formulary alternative failure records.

❌ Weak Statement	✅ Strong Statement
“I need Wegovy because Medicare should cover weight loss drugs now.”	“Beneficiary (BMI 36.1, ICD-10 E66.01) requests formulary exception for Wegovy after documented failure of metformin 1000mg BID × 90 days (<3% weight loss) and phentermine discontinuation due to tachycardia (HR 118 bpm). Covered alternatives are ineffective or intolerable per plan exception criteria.”
“My doctor says Ozempic and Wegovy are the same drug.”	“Prescriber (NPI documented) attests that semaglutide 2.4 mg (Wegovy) is required for obesity management at FDA-approved dose. Ozempic maximum dose (2 mg) produced subtherapeutic weight response (−4 lbs over 6 months) documented in attached visit notes dated [date].”
“Please approve my Wegovy — it is FDA approved.”	“I request expedited formulary exception under Part D appeal rights. Attached: prescriber statement, BMI records, HbA1c 6.4% (prediabetes E11.65), hypertension (I10), and step therapy documentation per denial rationale. Request 72-hour expedited decision.”

Need a Medicare GLP-1 Appeal Letter?

AppealFlow's GLP-1 generator drafts formulary exception language citing FDA criteria, failed therapies, and Part D appeal rights — ready in under 60 seconds.

Generate GLP-1 Appeal Letter

Submitting Through Medicare Part D Portals and PBMs

Key Takeaway: Part D plans contract with Pharmacy Benefit Managers for drug claims. Formulary exception requests go to your Part D plan first — not directly to CoverMyMeds or Express Scripts unless your plan routes through those platforms.

Platform	Used By	How to Use for Part D
Medicare.gov Plan Compare	All Part D beneficiaries	Search formulary by drug name before enrolling or requesting exceptions
CoverMyMeds	Some Part D plans; prescriber-initiated PA	Prescriber submits via key code; attach exception documentation
Express Scripts	Many national Part D plans	Member portal → Pharmacy → Coverage Determination / Appeal
OptumRx	UnitedHealthcare Part D plans	OptumRx.com → Medicare member login → Formulary Exception Request

Your Medicare card lists your Part D plan name and customer service number. Call that number to confirm the correct submission channel before your prescriber sends documentation to the wrong PBM portal.

Part D Appeal Levels After Formulary Exception Denial

Key Takeaway: Medicare Part D provides a structured five-level appeal process ending with federal court review. Most beneficiaries resolve cases at redetermination or Independent Review Entity (IRE) level when documentation is complete.

Redetermination: Request from your Part D plan within 60 days of denial. Plan must respond within 7 days (expedited) or 45 days (standard).
Reconsideration by Independent Review Entity: File within 60 days of redetermination denial. IRE is not employed by your plan.
ALJ hearing: Available if IRE denies and the case meets the dollar threshold.
Medicare Appeals Council review: Further federal review if ALJ decision is unfavorable.
Federal district court: Final judicial option for unresolved Part D disputes.

Realistic Timelines and Success Rates for Medicare GLP-1 Appeals

Key Takeaway: Plan for 7–45 days per Part D appeal level. Formulary exceptions for obesity GLP-1s succeed roughly 25–40% with complete documentation — lower than commercial plans because the statutory exclusion is explicit. Diabetes-indication GLP-1 appeals succeed more often.

I want to be direct: Medicare's obesity drug exclusion is a structural barrier, not a paperwork problem. A well-written appeal letter helps — but it cannot override a plan that applies the exclusion consistently. Your best outcomes come from documenting why covered alternatives fail and invoking Part D exception criteria precisely.

Common myth: News coverage about GLP-1 popularity means Medicare automatically covers Wegovy. Part D formularies update annually — check your current plan's drug list every enrollment period. Patient assistance programs (Novo Nordisk Wegovy savings card) may help while appeals are pending for non-Medicare patients, but Medicare anti-kickback rules limit manufacturer subsidy options for beneficiaries.

Five Mistakes That Kill Medicare Wegovy Appeals

Key Takeaway: Resubmitting the same prior auth form is not a Part D appeal. Formulary exceptions and redeterminations are separate processes with different deadlines and legal protections.

Assuming FDA approval equals Part D coverage. The exclusion applies regardless of FDA obesity indication.
Missing the 60-day appeal deadline. Part D appeal rights expire — no exceptions for late filing.
Generic prescriber letters. One-paragraph notes without failed therapy documentation rarely succeed.
Wrong diagnosis coding. E66.x obesity codes trigger exclusion review; ensure clinical record supports the documented indication.
Stopping after first denial. IRE review is your strongest remaining option — many patients abandon the process too early.

Frequently Asked Questions

Answers to the most common Medicare Part D Wegovy coverage questions from beneficiaries and advocates.

Generate Your Free GLP-1 Appeal Letter

AppealFlow.net drafts a formal Part D formulary exception letter citing FDA indication criteria and your specific denial reason — edit live, then download as PDF or Word. No account required.

Generate Free Appeal Letter GLP-1 Specialized Tool

100% Free
No Signup
PDF & Word Export

Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. AppealFlow.net is not a healthcare provider or law firm. Success rates cited are estimates based on industry advocacy data and vary by plan. Always review appeal letters with your prescriber before submission. For medical emergencies, call 911. See our full disclaimer.